Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-Activated Protein Kinase (AMPK) have been proposed...

Descripción completa

Detalles Bibliográficos
Autores principales: Esquejo, Ryan M., Salatto, Christopher T., Delmore, Jake, Albuquerque, Bina, Reyes, Allan, Shi, Yuji, Moccia, Rob, Cokorinos, Emily, Peloquin, Matthew, Monetti, Mara, Barricklow, Jason, Bollinger, Eliza, Smith, Brennan K., Day, Emily A., Nguyen, Chuong, Geoghegan, Kieran F., Kreeger, John M., Opsahl, Alan, Ward, Jessica, Kalgutkar, Amit S., Tess, David, Butler, Lynne, Shirai, Norimitsu, Osborne, Timothy F., Steinberg, Gregory R., Birnbaum, Morris J., Cameron, Kimberly O., Miller, Russell A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014578/
https://www.ncbi.nlm.nih.gov/pubmed/29673898
http://dx.doi.org/10.1016/j.ebiom.2018.04.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014578/
https://www.ncbi.nlm.nih.gov/pubmed/29673898
http://dx.doi.org/10.1016/j.ebiom.2018.04.009

Ejemplares similares